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with left main and or triple vessel CAD often have significant co-morbidities making them
extremely high risk for mortality & morbidity related to post-CABG recovery. For such
patients Impella supported PCI is feasible.
Methods: Retrospective analysis of 225 procedures in 200 patients undergoing high risk
PCI with Impella assist between 8/2008 and 5/2012 from an inner city hospital with
multiple co-morbidities was evaluated in this study. We present their demographics,
in-hospital and 30 day survival along with co-morbidities (STS, EUROSCORE I & II and
PARSONNET) and coronary risk profile based on Syntax scoring.
Patient Characteristics
Age (mean) 78.4 years	/ 8.3
Caucasians/African-americans 55%/42%
Gender % ( males/females ) 73.5/26.5
LVEF (mean) 24%	/ 12%
Co-morbidities
Prior MI 72%
Prior PCI 69%
Diabetes (on medications oral/insulin) 67%
PVD 44%
CKD Stage IV/V (GFR  30) 36%
COPD ( on inhalers ) 32%
Prior CABG 28%
Co-morbidity based mortality Risk Scoring
STS – Mean Risk of Procedural Mortality 6.3%	/ 4.8 %
STS – mean Mortality or morbidity 36.8%	/ 13.7%
Mean EuroSCORE II predicted mortality 16.67%	/ 9.8%
Mean EUROSCORE predicted mortality(logistic) 40.5%	/ 18%
Mean Parsonnet predicted 30 day mortality 20.5%	/ 10.3%
Coronary Lesion Characteristics and Syntax risk scoring
Left Main 	 multivessel 43%
Multivessel 34%
Syntax Scoring 0-22 52%
Syntax Score 23-32 38%
Syntax Score  33 10%
Results: Among the 200 patients who underwent 225 high-risk PCI with Impella support,
there was only 1/225 (0.44 %) in-hospital mortality. The mean length of hospital stay was
3.71 	/ 1.9 days. 2 patients were lost to follow up, of the remaining 197 patients, the
30 day survival was 99.5%.
Conclusions: Our experience demonstrates that use of the Impella 2.5 for prophylactic
circulatory support during high-risk PCI in the “real world” is safe and feasible, expanding
treatable patient populations. The excellent outcomes rival or exceed those for published
contemporary CABG series for low, intermediate or high risk patients.
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Background: There are a few data of clinical outcome of new-onset acute heart failure
(AHF) during hospitalization in patients with acute myocardial infarction (AMI) under-
went successful revascularization.
Methods: We analyzed 7,064 AMI patients with Killip class I at admission underwent
successful percutaneous coronary intervention from Korea Acute Myocardial Infarction
Registry between Oct. 2005 and Jan. 2008. Of these, 120 patients (1.7%) suffered from
new-onset AHF during their hospitalization.
Results: Patients with AHF were older and more common in female gender and ST
elevation MI than those without AHF. Patients with AHF also were more likely to have
low left ventricular ejection fraction (LVEF) and low creatinine clearance than those
without AHF. Multi-vessel disease or left main disease and complex target lesion and
incomplete revascularization were more frequently in patients with AHF than those
without AHF (p0.005 respectively). Patients with AHF had significantly higher
incidence of in-hospital mortality and l-year mortality than those without AHF (23.3% vs.
0.5%; 38.2% vs. 2.9%, p0.001 respectively). Multiple regression analysis demonstrated
that new-onset AHF [Odds ratio (OR)18.533; 95% Confidence interval (CI)7.505-
45.764], ventricular tachycardia/fibrillation (OR8.826; 95% CI3.123-24.949), LVEF
50% (OR4.092; 95% CI1.741-9.620) and age (OR1.058; 95% CI1.013-1.106)
were independent predictors for in-hospital mortality in AMI patients. The independent
predictors of development of new-onset AHF in patient with AMI underwent successful
revascularization were ventricular tachycardia/fibrillation (OR10.567; 95% CI6.089-
18.336), LVEF 50% (OR2.037; 95% CI1.298-3.197), ST elevation MI
(OR2.522; 95% CI1.369-4.646), SBP 120mmHg (OR1.839; 95% CI1.186-
2.852) and Atrioventricular block (OR3.062; 95% CI1.276-7.177).
Conclusions: New-onset AHF rarely occurred in patients with AMI underwent
successful revascularization, however, was highly associated with in-hospital
mortality. Therefore, even though they underwent successful revascularization,
intensive treatment and careful monitoring should be required for patients with
high risk of new-onset AHF.
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Background: The RCP is a 14 French collapsible percutaneous cardiovascular support
device positioned in the descending part of the thoracic aorta via the femoral artery. A 10
patient first in man study demonstrated device safety and significant improvement in renal
function among high risk PCI patients. We now report haemodynamic and renal efficacy
in patients with ADHF.
Methods: Prospective non randomised multi-centre study seeking to recruit 20 patients
with ADHF with a need for inotropic or mechanical circulatory support with: i) EF 
30% ii) Cardiac index(CI) 2.2 L/min/m2 Outcome measures included: 1) Cardiac index
(CI) 2) Pulmonary Capillary Wedge Pressure (PCWP) 3) Urine output/serum creatinine/
eGFR 4) Vascular/device complications 5) 30 day mortality.
Results: INTERIM ANALYSIS (n14) The mean age of the study group was 64.5
years.The intended RCP treatment period was 24 hours. During RCP treatment there was
a 30% improvement in mean Cardiac Index (CI) measured at 24 hours (1.85 to 2.45
L/min/m2 p0.08), and a concomitant trend towards reduction in PCWP at 24 hours of
26% (27 to 20 mmHg p0.28). RCP insertion prompted substantial diuresis. Urine output
doubled over the first 24 hours compared to baseline (74 ml/hr vs 157 ml/hr p0.006).
This was associated with significantly improved renal function, a 22% reduction in serum
creatinine at 24 hours (174 to 142 umol/L p0.0002), and a increase in eGFR from 50.2
ml/min to 61 ml/min (p0.001). 2 patients previously refused cardiac transplantation
were reassessed and successfully transplanted within 9 months of RCP treatment on the
basis of demonstrable renal reversibility. There were no vascular or device complications.
There were 2 deaths at 30 days, one from multi-organ failure and sepsis, and one from
intractable heart failure - neither were device related.
Conclusions: The Reitan Catheter Pump improves haemodynamics and renal function in
the acutely decompensated cardiac patient, and may have a role in suggesting renal
reversibility in potential cardiac transplant patients. Further data will be reported at
recruitment completion.
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Background: The increased use of continuous-flow LVADs in advanced heart failure
has led to marked changes in the management of patients with this condition. However,
secondary AI can become a significant complication. Our objective was to assess the
effectiveness of a novel percutaneous method to treat left ventricular assist device
(LVAD)-associated severe aortic insufficiency (AI) in a series of patients determined to be
poor reoperative candidates.
Methods: Five patients with continuous-flow LVADs and severe post-LVAD AI
underwent percutaneous transcatheter aortic valve (AV) closure with the Amplatzer™
Cribiform device (AGA Medical, Plymouth, MN) between September to October 2011 at
a single quaternary care academic medical center. All patients had LVADs implanted as
destination therapy. LVAD parameters, hemodynamics, and echocardiographic measure-
ments were obtained before and after AV closure.
Results: All patients underwent successful closure with the Amplatzer™ Cribiform
device via a percutaneous transcatheter femoral approach with a significant reduction of
AI from severe to trivial (p0.05). Cardiac hemodynamics improved and the pulmonary
capillary wedge pressure (PCWP) was reduced in all patients (p0.05). There was no
change in mitral or tricuspid regurgitation, LVAD power or pulsatility index.
Conclusions: Percutaneous transcatheter closure of the aortic valve effectively treats
LVAD-associated AI and reduces PCWP. This procedure should be considered to treat
LVAD-associated AI in patients who are poor candidates for repeat operation. Further
data is needed to assess long-term results.
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